Showcasing Capabilities in Cell and Gene Therapy CDMO Services

GC Cell announced on May 4 that it successfully concluded its participation in ‘BIOKOREA 2026,’ held from the 28th to the 30th of last month, by showcasing its capabilities in Cell & Gene Therapy (CGT) CDMO (Contract Development and Manufacturing Organization) services.


BIOKOREA 2026 is a global bio industry event that brings together domestic and international pharmaceutical and biotechnology companies as well as research institutions, providing a platform to share the latest technologies and business collaboration opportunities.

A representative from GC Cell is welcoming visitors at 'BIOKOREA 2026,' held from the 28th to the 30th of last month. GC Cell

A representative from GC Cell is welcoming visitors at 'BIOKOREA 2026,' held from the 28th to the 30th of last month. GC Cell

View original image

At this event, GC Cell operated an exhibition booth and focused on presenting its integrated services in the cell and gene therapy CDMO sector, including regulatory affairs and logistics services. The company particularly highlighted its full-cycle support platform, spanning from early-stage research and development to clinical and commercial production, and emphasized its partnership strategy based on customized development and manufacturing services for clients.


During the event, numerous representatives from domestic and overseas pharmaceutical and bio companies visited the booth, showing great interest in GC Cell’s CDMO services, and explored new partnership opportunities through a variety of business meetings.


GC Cell has established a global-level quality management system and production capabilities based on its accumulated experience in the development and manufacturing of cell and gene therapies. Through this, the company provides flexible CDMO services that meet the diverse needs of clients and continues to strengthen its competitiveness in the advanced biopharmaceutical sector.



Seongyong Won, CEO of GC Cell, stated, “Through BIOKOREA 2026, we were able to effectively introduce GC Cell’s CDMO capabilities and integrated platform for cell and gene therapies,” adding, “We will continue to strengthen our position in the global CDMO market by offering customized services and differentiated technological expertise.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing